口腔癌患者におけるTS-1 投与で生じる有害事象の検討 —2週投薬1週休薬によって発現する皮疹を中心に—

DOI Web Site 参考文献16件

書誌事項

タイトル別名
  • Adverse events of TS-1 administered to oral cancer patients:　Rash associated with a regimen of 2-week treatment followed by a 1-week rest
  • 口腔癌患者におけるTS-1投与で生じる有害事象の検討--2週投薬1週休薬によって発現する皮疹を中心に
  • コウクウガン カンジャ ニ オケル TS 1 トウヨ デ ショウジル ユウガイ ジショウ ノ ケントウ 2シュウ トウヤク 1 シュウキュウヤク ニ ヨッテ ハツゲン スル ヒシン オ チュウシン ニ

この論文をさがす

抄録

We evaluated adverse events after administration of TS-1 to patients with oral cancer. The subjects were 29 patients with oral cancer in whom TS-1 was administered as preoperative treatment at our department in 2006 and 2007. Each course of TS-1 （80-120 mg/day）consisted of 14-day drug treatment, followed by a 7-day rest. As adverse events, skin rash occurred in 6 of the 29 patients, oral aphtha, diarrhea, and general malaise in 3 each, pain around the eyeball and myelosuppression in 2 each, and gastric discomfort, oral dryness, taste disorder, and erosion at the angle of the mouth in 1 each. All events were grade as 1 or 2. The incidence of rash has been considered to be lower than that of gastrointestinal disorders or myelosuppression, but was the highest in this study. In 4 of the 6 patients with rash, symptoms improved after the external application of steroids and oral administration of antihistamines and antiallergic drugs, allowing treatment with TS-1 to be continued. Rash occurred early after the start of TS-1 treatment.

収録刊行物

参考文献 (16)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ